Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the 13 Small Cap Stocks Analysts Are Bullish On. On May 14, JonesTrading ...

JPM's strong NII outlook, NVS's blockbuster pipeline, and T's wireless momentum anchor today's top analyst picks.

FDA approved to help select patients with metastatic prostate cancer for radioligand therapy before chemotherapy.

Common isotopes include lutetium-177, actinium-225, gallium-68 (diagnostic), fluorine-18, and radium-223. The therapy combines isotopic radiance with molecular targeting-e.g., PSMA in prostate cancer ...

Telix Pharmaceuticals’ Illuccix gets US FDA label expansion to add patient selection for radioligand therapy: Melbourne, Australia Wednesday, June 25, 2025, 17:00 Hrs [IST] Melb ...

Northwell’s Phelps Hospital is the first and only medical facility in New York State between the Bronx and Albany to offer Pluvicto, a groundbreaking treatment for men with advanced prostate […] ...

Broker UBS believes the three-year rout of ASX healthcare stocks is near an end and it has promoted Cochlear and Resmed to ...

Illuccix® (kit for the preparation of gallium-68 ( 68 Ga) gozetotide injection), Telix's first generation PSMA-PET imaging ...

The firm hopes to overcome common dose-limiting toxicities with its PSMA-targeted radiotherapy while boosting potency versus competitors.

Pluvicto has already overtaken predecessor radioligand therapy Lutathera (177Lu- oxodotreotide) for neuroendocrine tumours, which rose 22% to $149 million in the first quarter.

Pluvicto meanwhile brought in $980 million in 2023, and Novartis is modelling peak sales above $2 billion if it expands into earlier lines of therapy in PSMA-positive metastatic castration ...